MRSN Mersana Therapeutics, Inc.Stock Price & Overview
$2.47
Charts
Quant Ranking
MRSN Analysis
MRSN News
Latest Headlines
Ratings Summary
People Also Follow
Similar to MRSN
ETFs Holding MRSN
MRSN Company Profile
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
MRSN Revenue
MRSN Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
MRSN Ownership
MRSN Peers
Risk
Technicals
MRSN Transcripts
Investor Presentations
MRSN SEC Filings
Press Releases
MRSN Income Statement
MRSN Balance Sheet
MRSN Cash Flow Statement
MRSN Long Term Solvency
Discover More
You may be interested in: